Effect of Interferon-α on Experimental Septal Fibrosis of the Liver - Study with a New Model

Memorias do Instituto Oswaldo Cruz

Volumn 96, Issue 3, 2001, Pages 343-348

  De Souza, Marcia Maria ^a   Paraná, Raymundo ^b   Trepo, Christian ^c   Barbosa Jr , Aryon A ^a   Oliveira, Irismar ^b   Andrade, Zilton A ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c INSERM   (France)

Author keywords

Capillaria hepatica; Hepatic fibrosis; Interferon

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL RESPONSE MODIFIER; HYDROXYPROLINE;

ANIMAL; ARTICLE; CAPILLARIA; CASE CONTROL STUDY; CHEMISTRY; DISEASE MODEL; EXPERIMENTAL LIVER CIRRHOSIS; FEMALE; LIVER; MALE; PATHOLOGY; RAT; WISTAR RAT;

ANIMALS; BIOLOGICAL RESPONSE MODIFIERS; CAPILLARIA; CASE-CONTROL STUDIES; DISEASE MODELS, ANIMAL; FEMALE; HYDROXYPROLINE; INTERFERON-ALPHA; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; RATS; RATS, WISTAR;

EID: 0035315932     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0074-02762001000300010     Document Type: Article

References (20)

1. Andrade ZA 1991. Contribution to the study of septal fibrosis of the liver. Internat J ExperPathol 72: 553-562.
2. Bergman I, Loxley R 1963. Improved and simplified methods for the spectrophotometric determination of hydroxyproline. Ann Chem 35: 1961-1965.
3. Bhunchet E, Eishi Y, Wake K 1996. Contribution of immune response to the hepatic fibrosis induced by porcine serum. Hepatology 23: 811-817.
4. Cotler SJ, Jensen DM 1999. Management of chronic hepatitis C. In E Krawitt, Medical Menagement of Liver Disease, Marcel Decker, New York, p. 99-123.
5. Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, Bartolomei-Portal I, Barange K, Moussalli J 1998. Reinforced regimen of interferon alfa-2b reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentric randomised trial. J Hepatol 29: 224-232.
6. Ferreira LA, Andrade ZA 1993. Capillaria hepatica: a cause of septal fibrosis of the liver. Mem Inst Oswaldo Cruz 88: 441-447.
7. Fort J, Pilette C, Veal N, Oberti F, Gallois Y, Douay O, Rosenbnaum J, Cales P 1998. Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats. J Hepatol 29: 263-270.
8. Geerts A, De Bleser P, Hautekeete ML, Niki T, Wisse E 1999. Fat-storing (Ito) cell biology. In IM Arias, JL Boyer, N Fausto, WB Jakoby, DA Schachter, DA Shafritz (eds), The Liver: Biology and Pathobiology, 3rd ed., Raven Press, New York, p. 819-838.
9. Guerret S, Desmoulière A, Chossegros P, Costa AMA, Badid C, Trépo C, Grimaud JA, Chevallier M 1999. Long-term administration of interferon-a in non-responder patients with chronic hepatitis C: follow up of liver fibrosis over 5 years. J Viral Hepatol 6: 125-133.
10. Guido M, Rugge M, Chemello L, Leandro G, Fattovich G, Giustina G, Cassaro M, Alberti A 1996. Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. J Hepatol 24: 301-307.
11. Horisberger MA, Staritzky K 1987. A recombinant human interferon-α B/D hybrid with a broad host-range. J Gen Virol 68: 945-948.
12. Junqueira LCU, Bignolas G, Brentani R 1979. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 11: 447-455.
13. Mallat A, Préaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P 1995. Interferon α and γ inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 21: 1003-1010.
14. Manabe N, Chevalier M, Chossegros P, Causse X, Guerret S, Trépo C, Grimaud JA 1993. Interferon α-2b therapy reduces Iver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology 18: 1344-1349.
15. Meister A, Uzé G, Mogensen KE, Gresser I, Tovey MG, Grütter M, Meyer F 1986. Biological activities and receptor binding of two human recombinant interferons and their hybrids. J Gen Virol 67: 1633-1643.
16. Moreno MG, Muriel P 1995. Remission of liver fibrosis by interferon-α. Biochem Pharmacol 50: 515-520.
17. Paronetto F, Popper H 1966. Chronic liver imjury induced by immunologic reactions. Cirrhosis following immunization with heterologous sera. Am J Pathol 40: 1087-1101.
18. Pilette C, Fort J, Rifflet H, Calés P 1997. Effects anti-fibrosants des interferon. Mécanismes d' action et perspectives thérapeutiques. Gastroenterol Clin Biol 21: 466-471.
19. Poynard T, Bedossa P, Chevalier M, Mathurim P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput JC 1995. A comparison of three different alfa-2 regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicentric studiy group. New Engl J Med 332: 1457-1462.
20. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kurori T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M 2000. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Int Med 132: 517-524.